The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Tukysa (tucatinib) mixed with Herceptin (trastuzumab) and Perjeta (pertuzumab) prolonged progression-free survival as a frontline upkeep method in contrast with placebo plus...
The addition of the immune checkpoint inhibitor Tecentriq (atezolizumab) to neoadjuvant chemotherapy and as a single agent adjuvant remedy numerically elevated the...
